[1] VENKETASUBRAMANIAN N, YOON BW, PANDIAN J, et al. Erratum:stroke epidemiology in South, East, and South-East Asia:A review[J]. J Stroke, 2018,20(1):142.
[2] SLOMKA M, KUSZCZYK M, LAZAREWICZ JW, et al. NMDA receptor antagonists MK-801 and memantine induce tolerance to oxygen and glucose deprivation in primary cultures of rat cerebellar granule cells[J]. Acta Neurobiol Exp (Wars), 2014, 74(4):396-404.
[3] AMANTEA D, BAGETTA G. Excitatory and inhibitory amino acid neurotransmitters in stroke:from neurotoxicity to ischemic tolerance[J]. Curr Opin Pharmacol, 2017, 35:111-119.
[4] ERKKINEN MG, KIM MO, GESCHWIND MD. Clinical neurology and epidemiology of the major neurodegenerative diseases[J]. Cold Spring Harb Perspect Biol, 2017, 10(4):a033118.
[5] WU QJ, TYMIANSKI M. Targeting NMDA receptors in stroke:new hope in neuroprotection[J]. Mol Brain, 2018, 11(1):15.
[6] MATTSON MP. Excitotoxicity[M]//Neurodegeneration.Hoboken:John Wiley & Sons, Ltd, 2017.
[7] DO S, LUO JH, QIU S.Mechanism of NMDA receptor-dependent neuronal survival and neuroprotection[J]. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2011, 40(4):440-445.
[8] LIU DD, YANG Q, LI ST. Activation of extrasynaptic NMDA receptors induces LTD in rat hippocampal CA1 neurons[J]. Brain Res Bull, 2013, 93(4):10-16.
[9] 韩思雨, 肇玉明. N-甲基-D-天冬氨酸受体在脑中风发病机制中的作用研究进展[J]. 中国药学杂志, 2017, 52(17):1483-1487.
[10] 骆媛, 王永安. N-甲基-D-天冬氨酸受体激活在脑缺血中的神经保护及神经毒性作用研究进展[J]. 中国药理学与毒理学杂志, 2012, 26(3):379-382.
[11] LIU SB, ZHAO MG. Neuroprotective effect of estrogen:role of nonsynaptic NR2B-containing NMDA receptors[J]. Brain Res Bull, 2013, 93(4):27-31.
[12] RUBIO-CASILLAS A, FERNáNDEZ-GUASTI A. The dose makes the poison:from glutamate-mediated neurogenesis to neuronal atrophy and depression[J]. Rev Neurosci, 2016, 27(6):599-622.
[13] CHAKRABORTY A, MURPHY S, COLEMAN N. The role of NMDA receptors in neural stem cell proliferation and differentiation[J]. Stem Cells Dev, 2017, 26(11):798-807.
[14] ARVIDSSON A, KOKAIA Z, LINDVALL O. N -methyl-D -aspartate receptor-mediated increase of neurogenesis in adult rat dentate gyrus following stroke[J]. Eur J Neurosci, 2001, 14(1):10-18.
[15] 邓娜. 美金刚治疗缺血性脑卒中后失语的疗效观察[D].重庆:重庆医科大学, 2015.
[16] WILD AR, AKYOL E, BROTHWELL SL, et al. Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones[J]. Neuropharmacology, 2013, 73(5):138-146.
[17] VAN WAGENINGEN H, JORGENSEN HA, SPECHT K, et al. The effects of the glutamate antagonist memantine on brain activation to an auditory perception task[J]. Hum Brain Mapp, 2009, 30(11):3616-3624.
[18] MEISNER F, SCHELLER C, KNEITZ S, et al. Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques:a novel pharmacological action of memantine[J]. Neuropsychopharmacology, 2008, 33(9):2228-2236.
[19] LOPEZ-VALDES HE, CLARKSON AN, AO Y, et al. Memantine enhances recovery from stroke[J]. Stroke, 2014, 45(7):2093-2100.
[20] LIU C, LIN N, WU B, et al. Neuroprotective effect of memantine combined with topiramate in hypoxic-ischemic brain injury[J]. Brain Res, 2009, 1282:173-182.
[21] CHEN B, WANG G, LI W, et al. Memantine attenuates cell apoptosis by suppressing the calpain-caspase-3 pathway in an experimental model of ischemic stroke[J]. Exp Cell Res, 2017, 351(2):163-172.
[22] LANDUCCI E, FILIPPI L, GERACE E, et al. Neuroprotective effects of topiramate and memantine in combination with hypothermia in hypoxic-ischemic brain injury in vitro and in vivo[J]. Neurosci Lett, 2018, 668:103-107.
[23] TAKAHASHI H, XIA P, CUI J, et al. Corrigendum:Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease[J]. Sci Rep, 2016, 6(1):20750.
[24] 郭叶群. 盐酸美金刚对大鼠大脑中动脉闭塞后同侧丘脑继发损害的保护作用及其机制研究[D].广州:暨南大学, 2015.
[25] WANG YC, SANCHEZ-MENDOZA EH, DOEPPNER TR, et al. Post-acute delivery of memantine promotes post-ischemic neurological recovery, peri-infarct tissue remodeling, and contralesional brain plasticity[J]. J Cereb Blood Flow Metab, 2017, 37(3):980-993.
[26] TROTMAN M, VERMEHREN P, GIBSON CL, et al. The dichotomy of memantine treatment for ischemic stroke:dose-dependent protective and detrimental effects[J]. J Cereb Blood Flow Metab, 2015, 35(2):230-239.
[27] ORGOGOZO JM, RIGAUD AS, STOFFLER A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia:a randomized, placebo-controlled trial (MMM 300)[J]. Stroke, 2002, 33(7):1834-1839.
[28] KAFI H, SALAMZADEH J, BELADIMOGHADAM N, et al. Study of the neuroprotective effects of memantine in patients with mild to moderate ischemic stroke[J]. Iran J Pharm Res, 2014, 13(2):591-598.
[29] BERTHIER ML, GREEN C, LARA JP, et al. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia[J]. Ann Neurol, 2009, 65(5):577-585.
[30] BARBANCHO MA, BERTHIER ML, NAVAS-SANCHEZ P, et al. Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia:An ERP study[J]. Brain Lang, 2015, 145-146:1-10.
[31] LUK'IANIUK EV, MALIUKOVA NG, SHKLOVSKⅡ VM, et al. The use of akatinol memantine in the residual phase of stroke[J].Zh Nevrol Psikhiatr Im SS korsakova,2010, 110(12 Pt2):28-33.